N -Acetylcysteine and a Specialized Preventive Intervention for Individuals at High Risk for Psychosis: A Randomized Double-Blind Multicenter Trial.
Sven WasserthalAna MuthesiusRené HurlemannStephan RuhrmannStefanie J SchmidtMartin HellmichFrauke Schultze-LutterJoachim KlosterkötterHendrik MüllerAndreas Meyer-LindenbergTimm B PoepplHenrik WalterDusan HirjakNikolaos KoutsoulerisAndreas J FallgatterAndreas BechdolfAnke Brockhaus-DumkeChristoph MulertAlexandra PhilipsenJoseph KambeitzPublished in: Schizophrenia bulletin open (2024)
The superiority of NAC or IPPI in preventing psychosis in patients with CHR-P compared to controls could not be statistically validated in this trial. However, results indicate a consistent pattern that warrants further testing of NAC as a promising and well-tolerated intervention for CHR patients in future trials with adequate statistical power.
Keyphrases
- phase iii
- randomized controlled trial
- study protocol
- clinical trial
- double blind
- phase ii
- transcription factor
- end stage renal disease
- ejection fraction
- newly diagnosed
- prognostic factors
- palliative care
- peritoneal dialysis
- cross sectional
- current status
- patient reported outcomes
- genome wide analysis
- patient reported